Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Subscribe To Our Newsletter & Stay Updated